For ASLAN Pharmaceuticals Limited [ASLN], Analyst sees a drop to $8.50. What next?

ASLAN Pharmaceuticals Limited [NASDAQ: ASLN] surged by $0.16 during the normal trading session on Tuesday and reaching a high of $2.29 during the day while it closed the day at $2.22. The company report on November 19, 2020 that ASLAN Pharmaceuticals to Present at Upcoming Piper Sandler Investor Conference.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, announced Dr Carl Firth, Chief Executive Officer of the company, will participate in a fireside chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference being held from 30 November to 3 December 2020.

A replay of the pre-recorded fireside chat will be available from November 23, 2020 in the Investor Relations section of ASLAN’s website at www.aslanpharma.com. The replay will be available for 30 days. ASLAN will be participating in 1×1 meetings on 30 November to 3 December 2020, meetings may be requested exclusively via Piper Sandler.

ASLAN Pharmaceuticals Limited stock has also gained 19.35% of its value over the past 7 days. However, ASLN stock has inclined by 47.02% in the 3 months of the year. Over the past six months meanwhile, it has gained 19.35% and gained 9.36% year-on date.

The market cap for ASLN stock reached $75.92 million, with 37.99 million shares outstanding and 37.99 million shares in the current float. Compared to the average trading volume of 392.28K shares, ASLN reached a trading volume of 1283525 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about ASLAN Pharmaceuticals Limited [ASLN]:

H.C. Wainwright have made an estimate for ASLAN Pharmaceuticals Limited shares, keeping their opinion on the stock as Buy, with their previous recommendation back on January 14, 2019.

The Average True Range (ATR) for ASLAN Pharmaceuticals Limited is set at 0.16, with the Price to Sales ratio for ASLN stock in the period of the last 12 months amounting to 400.21.

ASLN stock trade performance evaluation

ASLAN Pharmaceuticals Limited [ASLN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 19.35. With this latest performance, ASLN shares gained by 38.75% in over the last four-week period, additionally plugging by 19.35% over the last 6 months – not to mention a rise of 5.35% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ASLN stock in for the last two-week period is set at 64.18, with the RSI for the last a single of trading hit 66.57, and the three-weeks RSI is set at 62.16 for ASLAN Pharmaceuticals Limited [ASLN]. The present Moving Average for the last 50 days of trading for this stock 1.80, while it was recorded at 2.09 for the last single week of trading, and 1.68 for the last 200 days.

ASLAN Pharmaceuticals Limited [ASLN]: An insightful look at the core fundamentals

Operating Margin for any stock indicates how profitable investing would be, and ASLAN Pharmaceuticals Limited [ASLN] shares currently have an operating margin of -751.87 and a Gross Margin at +71.55. ASLAN Pharmaceuticals Limited’s Net Margin is presently recorded at -1570.52.

Return on Total Capital for ASLN is now -75.54, given the latest momentum, and Return on Invested Capital for the company is -161.41. Return on Equity for this stock declined to -326.19, with Return on Assets sitting at -123.62. Additionally, ASLN Total Debt to Total Capital is recorded at 110.04, with Total Debt to Total Assets ending up at 78.75.

ASLAN Pharmaceuticals Limited’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.20 and a Current Ratio set at 3.20.

Earnings per share (EPS) analysis for ASLAN Pharmaceuticals Limited [ASLN] stock

With the latest financial reports released by the company, ASLAN Pharmaceuticals Limited posted -0.9/share EPS, while the average EPS was predicted by analysts to be reported at -0.17/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -429.40%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ASLN.

ASLAN Pharmaceuticals Limited [ASLN]: Insider Ownership positions

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

Positions in ASLAN Pharmaceuticals Limited stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 2 institutional holders increased their position in ASLAN Pharmaceuticals Limited [NASDAQ:ASLN] by around 27,997 shares. Additionally, 5 investors decreased positions by around 108,245 shares, while 3 investors held positions by with 3,272,511 shares. The mentioned changes placed institutional holdings at 3,408,753 shares, according to the latest SEC report filing. ASLN stock had 1 new institutional investments in for a total of 16,306 shares, while 3 institutional investors sold positions of 50,594 shares during the same period.

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on skype
Skype
Share on reddit
Reddit

Leave a Comment

Your email address will not be published. Required fields are marked *

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam